Activity Report 2012

New Era of Open Innovation
Promotion through Networking

Create the future
via bio-innovation

Japan Bioindustry Association

Chairman

President

Executive Director

MichioOishi

Osamu
Nagayama

YoshiakiTsukamoto

Professor Emeritus,
University of Tokyo
President of KAZUSADNA Res. Inst.

Representative Director
Chairman & CEO
Chugai PharmaceuticalCo., Ltd.

Ex-Professor, Titech.
Ex-Director-Generalof Shikoku Bureau of METIIn the latter half of the 20th century, there was an expectation that throughJBA Activity Report 2012

contents
Mission3

1 Policy Proposal and Dialog

4

new biotechnologies such as DNA cloning and others based on molecularbiology, the world would witness the rise of new bioindustries. However, in
reality, there was no appreciable industrial movement that would meet those
expectations. Although it is generally accepted that a substantial time lag

2

Science Agora for Information
on Advanced Biotechnology

53Open Innovation
by Networking

64International Network

11

5

Establishing the Infrastructureof Bioindustry

13

usually exists between the emergence of a new science and that of a new
industry based on that technology, seemingly exaggerated expectations led toa situation where the enthusiasm for novel biotechnology-oriented industries
was almost extinguished. After more than a decade into the 21st century,
however, many people now believe that we are ﬁnally entering a new era ofdeveloping bioindustries based on these technologies.
Several achievements are already noteworthy: development of new drugs
utilizing the knowledge of molecular reactions in cells, selective administrationof medicines reﬂecting an individualʼs genetic background, development ofagricultural plants by genetic recombination and/or novel breeding methods
based on marker-assisted selection, and development of biofuels as a key tosolve environmental problems. It is clear that bioindustries are ﬁnally startingto take solid strides to the future.
Fortunately, the technologies that form the foundation for new bioindustries

About JBA

such as fermentation and breeding technologies have already been well

JBAʼs roots date back to Shusei Kyokai（the Distilled Spirits Institute）
established in 1942.
Its name, after being changed
to the Japanese Association ofIndustrial Fermentation, was renamed
as Japan Bioindustry Association（JBA）in 1987.

established in Japan. Accordingly, Japan is well positioned for the future
development of bioindustries in these ﬁelds. On the other hand, we should
also recognize that bioindustries have been diversiﬁed with unprecedented
speed, as new technologies and business models have emerged. Therefore,
needless to say, our bioindustries should not rest on their laurels in going
forward. As we enter this new era, the role of JBA will become increasingly
important, and because of this, I reaﬃrm my commitment to expand my roleand to contribute in new and creative ways as chairman of the organization.

Members
Corporate members ― 195 companies（pharmaceutical, food, chemical, cosmetic
and machinery companies）

Michio Oishi
Chairman of Board of Directors
Japan Bioindustry Association

Public members ― 92 organizations
Individual members ― 800（university and corporate researchers）

Budget: 500 million yen（2012）2

Activity Report 2012

MissionJBA contributes to bioindustry and related industries
in the ﬁelds of health, environment and food.
Our mission at JBA is to address the imminent problems facing mankind
such as those concerning climate change and biodiversity and to facilitate
implementation of appropriate measures as necessary, particularly byutilizing the latest developments in biosciences in an effective manner.
To that goal, one of the most important priorities of JBA is to formulate
and advance specific public policies through science-based reviews ofregulations as well as to craft strategies to strengthen collaboration
between industry, academia and government. Furthermore, to encourage
the exchange of vital data and information, we realize that cooperation andcommunication with like-minded organizations throughout the world is ofparamount importance. We are keenly aware of the value of providing free
and open access to information regarding new technologies and products toall those who are interested in opportunities for innovation. On a more local
level, our mission will also be expanded to help organize and develop regional
associations for bioindustries in Japan. As an example of such endeavors,
we hold an annual fair called BioJapan which comprises exhibitions, seminars
for academia and industry, and business to business matching.

1

Policy Proposal
and Dialog

42

Science Agora
for Information
on Advanced Biotechnology

International
Network

5

3

Open Innovation
by Networking

Establishing
the Infrastructureof Bioindustry

5 actions of3

1
actionPolicy Proposal and Dialog
JBA has oﬀered a variety of policy proposals and opportunities for dialog
for the sound development of biotechnology and bioindustry in cooperation
with member companies, universities and government bodies.

JBA cooperates in the activities of the Japan Association of Bioindustry
Executives* as an organization for integrating opinions and to make eﬀective
proposals for national policies. In addition, JBA endeavors to integrate opinionsfrom the standpoint of science by transmitting public comments, staging
events and planning seminars in BioJapan.

Member companies
Academic conference

Integrationof opinions

Business environment
Research environment
Maintenance/improvement

JBA & JABEX
Transmitting
publiccomments

Reﬂectionin the policies

Proposals

Present Cabinet, established in June 1999.
＊ Japan Association of Bioindustry Executives（JABEX）
The current number of JABEX members is 56. It is an extensive congregation of representatives ofJapanese bioindustry-related organizations and is addressing the problems of bioindustry,making proposals and taking action for the sound development of bioindustry.

Accomplishment ­1
In the “New Growth Strategy”（cabinet decision, June 2010）and the “4th Science and Technology Basic Plan of Japan”（cabinet
decision, August 2011）, the promotion of two major innovations, green innovation and life innovation, was raised as growth
pillars. The promotion of open innovation is considered to be an important policy to create new technologies and growing
industries. JBA hosted seminars which were delivered by policy planners of the respective ministries and agencies responsible
for these science and technology policy and bio-growth strategy, and facilitated the exchange of opinions. The seminars wereconducted eight times in 2011.

1. Seminar on “Strategy for research and development forthe creation of new bioindustries, bio-drug discovery,
medical devices, regenerative medicines, etc. andenvironmental industries, in the life ﬁeld”（April 11, 2011）

2. Seminar on “Biological weapons convention（BWC）and
its relation to the industry”（May 26, 2011）

3. Seminar on “Policy for the promotion of medical careinnovation, and its problems”（June 2, 2011）

biomass and its problems”（August 5, 2011）

6. Seminar on “Comprehensive economic partnership/TPP,
new green revolution and policy on agriculture, forestry
and ﬁsheries”（September 1, 2011）

7. Seminar on “Advanced research and developing
technologies of Overseas-BIO and their policy topics”（September 22, 2011）

4. Seminar on “Current situation of the evaluation of

8. Seminar on “Proceeding of Agriculture, Forestry andmedical drugs and medical devices, and their problems”

Fisheries as the 6th industry, and its problems”（January（August 2, 2011）11, 2012）

Accomplishment ­2

Public comments on government policies① Submitting a written opinion on the “Important Implementing
Action Plans（tentative）for Science and Technology in FY 2011”② Submitting a written opinion on the “Hokkaido regulation on theprotection of the cross with the cultivation of the genetically4

5. Seminar on “Current situation of the utilization ofmodified crops” and the “measures standards on theprotection of the cross with the cultivation of the genetically
modiﬁed crops” in Agricultural Policy Planning Departmentof Hokkaido

2

Activity Report 2012

actionScience Agora for Information
on Advanced Biotechnology
JBA is addressing the provision of biotechnology and new technical informationof the industry, discovery of seeds and industrialization in cooperation
with member companies, universities and government bodies.

JBA collects advanced biotechnology information in Japan and overseas,
conducts research on the latest development trends and discovers technicalseeds that may lead to new industries. JBA has those results shared incommon among the members through lectures and seminars. Furthermore,
JBA takes into consideration the project concept that should be deployedin cooperation with industry, government and academia.

Member companies
Academia（universities in general）

Advanced biotech
information

Seminars/Study meetings

Proposal
for a national project

Joint researchdevelopment allianceamong the members
Promotion of a research
project cooperatively among
academia, industry andthe government

Applications
from the public

Public agencies

Accomplishment
A total of 65 lectures, seminars, study meetings and visit tours were held by the study groups, and the total number of lecture
subjects was 238 topics, for a year-on-year increase of 126%, consisting of pharmaceuticals, medicinal care, environment,
manufacturing, foods and basic R&D, with a total of 3,718 participants. Timely and opportune subjects for lectures wereselected based on the proposal of each member, and in addition the subjects of Tohoku disaster-related and the reconstruction
were included. The university-originated seminars, information which promoted the utilization of the research projects of the
Ministry of Education, Culture, Sports, Science and Technology, and practical experience-oriented seminars to stimulate theutilization of public institutions were fully included.
Study meeting on “Biotechnology
toward the future”

Oﬀeringbio-tech
information

Presenterese teUniversity-launched selectedbio-seminar
Study group on fermentationand metabolism
Study group on new resource
bioconversion
Study group on alcohol fermentation& biomass utilization
Study group on bioengineering
Study group on biologicals
Glyco-innovation and industrial
technology forum

Medical care,
Medicine

Increase of seminars& audience

Government
23.5%
Industry
15.2%

No. ofeventsNo. ofparticipants

4000

80

Academia
61.3%

3718
70

3408

3500
3000

60

2599
Environment,
Manufacturing

Food,
Healthy foodFundamental
technology

Subject
Basic/
fundamentaltech 16.0%
Environment/
Manufacturing
29.0%

2500

50

Food/
healthyfood
10.9%

Medical care/
Medicine 44.1%

2000

40
30

1300

1500
1000

20
10

500

32 39 46 65
0【May 5, 2011 〜 March 25, 2012】2008 2009 2010 2011

0

5

3
actionOpen Innovation by Networking
In alliance with member companies, universities and the government, JBA provides opportunities
to help the development of biotechnology and industry

JBA annually holds an international comprehensive bio event,
BioJapan*, as an effective means to build a business platform forpromotion of alliances between parties, create opportunities for open
innovation, etc. Furthermore, through the activities of interactive
meetings of nationwide bio groups, primarily aiming for thedevelopment of drug-discovery bioclusters/bio-venture companies,
JBA not only promotes deeper exchanges with nationwide bioclusters
and bio groups but also aims to become the hub of those activities.

Venture members
Academia

Technology/seeds
Provision ofopportunities
supportJBA BioJapan
Interactive meetingon bio-clusters
Provision of dataon venture companies

Promotion of alliances
Open innovation
Promotion of business expansion

Member companies（Foreign companies）＊ BioJapan International comprehensive bio event that contributes to the publicity ofbiotechnology as a whole, starting in 1986 and having the longest history in Japan. It has been
held every year since 2004. It oﬀers exhibitions, business partnering meetings, technologicalpresentations by universities / venture companies and theme seminars

Accomplishment

BioJapan 2011
World Business Forum

New Bio Growth Strategy by Japan
BioJapan 2011 World Business Forum was held at
Paciﬁco Yokohama from Oct. 5 to Oct. 7.

【Subjects】1) Life, 2) Green, 3) Bioclusters & Ventures【Organizer】BioJapan Organizing Committee（JBA
and seven other organizations）and Nikkei BP Inc.
【Participants】Total number of visitors: 20,600.
【Exhibition】327 companies and organizations from allover the world presented their products and technologies
on the exhibition ﬂoor.

【Business partnering】Using a unique Web businessmatching system, participants of the event could get

6many chances to match their technological seeds toseeds with each other. There were 1,643 one-on-one
meetings during the event.

【Academic seeds presentations】These offered opportunities for planning joint research with corporations
through result presentations by 20 universities / publicresearch institutes.

Activity Report 2012

Opening Ceremony

Exhibitions

Welcome Address
Michio Oishi Chairman JBA
With a network of national and international biotechnology participants
gathered in BioJapan, we hope forfurther development of the industry.

The guests who attended the ceremony included Keiro Kitagami, viceminister of Economy, Trade andIndustry ; Yuji Kuroiwa, governor of
Kanagawa Prefecture ; Fumiko Hayashi,
mayor of the city of Yokohama ; andAtsushi Miura, deputy mayor of thecity of Kawasaki. They expressed
their expectations for the growth ofindustries based on biotechnology
and life innovation and BioJapan.

Fumiko Hayashi

Yuji Kuroiwa

Michio Oishi
Chairman JBA

Business Partnering
Keiro Kitagami

Business partnering presentations were held as one of themeans for achieving open innovation, the largest objective of
BioJapan. This year, 88 presentations were given by companies
to introduce their excellent new technologies and ideas.
Individual meetings using the Web Matching System werealso actively held. The system is used to search for businessseeds and alliance partners and helps arrange meeting times inaccordance with the schedules of both parties on the web. The
number of meetings held in business meeting areas was 952,
and the total number of meetings including those held inindividual booths was approximately 2,000.

Atsushi Miura

Keynote Speeches
The keynote speakers were Yasuchika Hasegawa, president
and representative director, Takeda Pharmaceutical Company
Limited, and Stephan Tanda, chairman, EuropaBio, and amember of the Managing Board of Directors, Royal DSM N.V.,
Holland. Mr. Hasegawa gave a speech titled “The Growth
Strategy in Japan” and proposed that Japan should promote
growth strategy based on innovation. Mr. Tanda gave a speech
titled “Life Sciences and Material Science-Building a Bio-Based
Economy: A Birdʼs Eye View of Biotech Trends and Markets,”
explaining the strategy of DSM and the status of biotechnology
industries in Europe and appealing for building a bio-based
economy founded on life science and materials science.

Yasuchika Hasegawa

Academic Seeds Presentations
These presentations are given to leading and large companies
in Japan and foreign counties in order to rapidly develop
prominent technological seeds at major universities andresearch institutes in Japan into educational-industrial joint
studies or technology transfers. A total of 20 universities andinstitutes presented the latest achievements in healthcare/drug
discovery, food, metabolomics, cleaning soil contaminatedwith radioactivity, bioenergy, biorefinery, biodevice, diseasemodel organisms, etc. through a total of 59 sessions.

Stephan Tanda

7

3Open Innovation by Networking

Seminars Given by the Sponsor
Moderator

Life Innovation Summit

Isao Teshirogi（President, Japan Pharmaceutical Manufacturers
Association）

Partnerships among Pharmaceutical Companies,
Bioventures, and Academia in Asia

Mr. Teshirogi explained the objectives of theseminar and the present state of pharmaceuticalindustries. In the United States, many drugs
originate from academic ventures. Although it is acknowledgedthat Japan and Europe are competent in basic studies, they aredeﬁnitely behind in commercialization.

Speakers & Panelists
Tatsumi Yamazaki（Chairman of Steering Committee, JBA）
Mr. Yamazaki explained pharmaceutical development in the futureand JBAʼs commitment.

Greg Wiederrecht（Vice president & head, Merck & Co. Inc.）
Mr. Wiederrecht spoke of the importance of open innovation inpharmaceutical development and alliance in the future.

Hao Yan（President & CEO, EPS Corporation）
Mr. Yan explained the activities of EPS Corporation.

Jonghoon Choi（Chief researcher, Korea Bio-Economy Research Center）
Mr. Choi spoke of changes in healthcare in Asia.

TatsumiYamazaki

Cluster Summit

Greg
Wiederrecht

Hao YanJonghoon Choi

Moderator Tsuneaki Sakata（Visiting professor, Osaka University）

Global Collaboration among Bioclusters

In reference to four bioclusters in foreign countries and Kobe andKurume, the present state, method, and issues of cooperation
between bioclusters and the industry in Japan were explained.

Speakers & Panelists
Ulf Åberg（Denmark: Senior business development
manager, Invest in Skane）

Mr. Åberg spoke of Medicon Valley（MV）located on the border between Denmarkand Sweden.

Karimah es Sabar（Canada: SVP Business & Strategic Aﬀairs, Center for Drug Researchand Development）

Ms. Sabar explained the Center for Drug Research and Development（CDRD）.

Andy Gearing（State of Victoria, Australia: CEO, Biocomm Squared）
Mr. Gearing explained the strengths of Australia in biotechnology, which is backed
by a thriving Australian economy.

Ulf Åberg

Karimah es
Sabar

Andy Gearing

Mario Pennisi Takashi Miki

Yoshifumi Ikeda

Mario Pennisi（State of Queensland, Australia: CEO, Life Science Queensland Limited）
Mr. Pennisi explained the Queensland Clinical Trials Network for supporting clinical
trials and Life Science Queensland.

Takashi Miki（Bureau director general, City of Kobe）
Mr. Miki explained the status of the rapidly developing Kobe Biomedical Innovation Cluster.

Yoshifumi Ikeda（Bio Project producer, Kurume Research Park Co. Ltd.）Mr. Ikeda explained the 10 years of the history of Kurume Research Park.

Green Innovation Summit
Moderator Hideaki Yukawa（Director, Research Institute of Innovative Technology for
the Earth, a Public Interest Incorporated Foundation）

Mr. Yukawa explained that biofuels are in the phase ofcommercialization.

Speakers & Panelists
Kenji Fujiyoshi（Chairman, Japan Chemical Industry
Association）

Mr. Fujiyoshi explained the commitment of theJapan Chemical Industry Association.

Shigeki Suzuki（Managing oﬃcer, Toyota Motor Corporation）

Mr. Suzuki explained the commitment of Toyota
Motor Corporation to achieving a green society.

Colin Michinson（Genencor Biomass Applications director）
Mr. Michinson explained the situation of the research and development of biocatalysts that enable the production of biofuels on
an industrial scale.

Steen Riisgaard（Novozymes A/S president and CEO）
Kenji Fujiyoshi Shigeki Suzuki Colin Michinson Steen Riisgaard

8

Mr. Riisgaard explained the inevitability of shifting to bioreﬁnery
and the role of enzyme catalysis.

Activity Report 2012

Support for Bio-venture Companies
and Bioclusters
As part of the operations to form a bioindustry
network that serves for local revitalization, JBA
has been convening the National Bio GroupInteraction Meeting. The network has been
formed with nationwide bio groups as a meansfor consultation of “All Japan,” and JBA has beenplaying a role in activity reports and informationexchange and as a facilitator for bio-clusters of
blocs around Japan. JBA, whose activities arediversified, works out new bio-related projects
and enhances the relationships between theblocs. In addition, JBA has also been promotinginteractive activities with overseas bioorganizations in recent years and continuously
sponsors the cluster summit as a means to
exchange opinions and promote interactions
with worldwide bio-clusters in BioJapan.

Through networking with nationwide bio groups and clusters,
JBA actively promotes interaction among industry, academia,
and government to support and foster bio-venture companies
and form bio-clusters.
National Bio GroupInteraction Meeting

Hokkaido
Bio-industry
Association

Tohoku-area
Bio-industry
Promotion
Association

Okinawa
TLO

Yokohama
Foundation
for theAdvancement ofLife Sciences（Base）

PharmaVally Center（Shizuoka）
NPO Kinki
Bio-industry
Development
Organization

ChugokuIndustrial
Innovation
CenterKurumeResearch
Park
ShikokuIndustry &Technology
Promotion
CenterNational Bioclusters
Networking
Metropolitan
Bio Network
Statistical data on
venture businessCorporate proﬁleof venture company
Support for overseas
expansion of
bio-venture business

Accomplishment

The 7th Biocluster Interaction Meeting（Cosponsor : JBA）
JBA held the National Biocluster Interactive Meeting
to promote industrialization of research results andbusiness seeds of each region that is taking a progressive
approach nationwide.
【Date】October 6, 2011
【Participants】62 Biocluster-related persons participatedfrom throughout Japan

Support for overseas expansionof bio-venture businessand cooperation with JETROThe exchange of opinions and opportunities for interaction
with worldwide bioclusters can be an effective means
to break through the bio-venture business environmentthat tends to be occluded. Therefore, by endeavoring topromote cooperation with overseas major bioclusters,
JBA supports the matching of bio-venture companies
and foreign corporations. Furthermore, in order tomultilaterally and effectively lead the activities tothe results, JBA has promoted further cooperation

through its activities with JETRO. JBA has a close
relationship with JETRO and supports bio-venturecompanies by participating in Bio-Europe Spring, etc. In
addition, the tie-up of activity in the JETRO BIOLINK held
concurrently with BioJapan is another example, wherea complementary relationship is being establishedthrough mutual activities.

Supportab

Corporate proﬁles
Supportfor preparing

Support for
matching
Participationin domestic
and overseas
exhibitionscdSupport for
exhibitions

Publicity

Follow-up

93Open Innovation by Networking

Metropolitan Bio Network activity
Management system of the Metropolitan
Bio Network
JBA sponsors activities in cooperation with members
in charge of business promotion consisting of member
venture companies, pharmaceutical companies,
support organizations (National Institute of Advanced
Industrial Science, JETRO, Tokyo Small and Medium

Business Investment & Consultation. Organization for
Small & Medium Enterprises and Regional Innovation,
Japan, KPMG AZSA LLC, and Japan Pharmaceutical
Manufacturers Association) and also with themembers of the operating committee consisting ofrepresentatives of member companies.

Preparation of statistical data on bio-venture business and directories
Statistical research on bio-venture businessPreparation of directories

JBA annually conducts questionnaire-based researchon nationwide bio-venture companies and carries
out classification and statistical analysis of bio-venturecompanies by prefecture and category. As a result inJanuary 2011, the number of bio-venture companies
reported on in Japan was 534.
In addition, JBA conducted research partnership withHitotsubashi University in an analysis based on JBAʼs“Statistical research on bio-venture companies（2011）.”

Under open innovation policy, directories on theorganization and latest information on bio-venturecompanies are an important means to share information.
JBA will continue to not only update the Metropolitan
Bio information but also prepare directories on nationwide bio-venture companies effectively capitalizing
on its own function as a base of activities. JBA is goingto organize the drug discovery-related bio-venture
information.

Number ofcompanies

600

534

500

Number of
bio-venture companies

400
300
200
100
0

94 995 996 997 998 999 000 001 002 003 004 005 006 007 008 009 010
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2

19

10

4

Activity Report 2012

actionInternational Network
JBA provides international information on biotechnology and bioindustry in cooperation
with member companies, universities and the government.

International activities of JBA include;( i ) Introduction/transmission of overseas bio-related information and events to the members(ii ) Transmission of information on Japanese bioindustry(iii) Transmission of opinions on international issues as Japanese bio-organization(iv) Interaction with overseas bio-organizations through participation in international bio-events( v ) Making requests for participation in BioJapan, and taking into consideration the wishes ofmember companies, JBA carries out the operations that are diﬃcult for a single individual
or corporation to accomplish

Information services

Member companies/Academia（Policies, investment
environment, research anddevelopment activities）

Venture members
Public members（METI, JETRO）
Domestic organizations（JPMA, STAFF）

Oﬀer/introduction ofcontacts for inquiry
Support for publicity
Consulting
Acceptance of missions
Holding seminars
Alliance

Building a network
International cooperation

Overseas bio-organizations
Foreign companies, OECD
Foreign embassies in Japan

Accomplishment

Creation of International Network
Written agreementswith overseas bio-organizations■ BIO（U.S.）
Mutual cooperation in the U.S. BIO,
BioJapan and BioAsia（since 2004）■ Swiss Biotech Association
Mutual cooperation（since 2005）■ Shanghai Biopharmaceutics Industries
Association
Mutual cooperation（since 2005）■ Russian Biotechnology Society
Mutual cooperation with no obligation（since 2009）■ CLIB2021（Bioclusters of the Rhein Region）/Cluster Bioindustrielle Biotechnologie
Mutual cooperation with no obligation（since 2009）■ DECHEMA
Mutual cooperation with no obligation（since 2010）■ KoreaBio
Mutual cooperation with no obligation（since 2010）■ Medical and Pharmaceutical commercial Association
Federation of Industry and Commerce（since 2012）11

4International Network

JBA events and activities for Open Innovation in 2011
■ Participation in the 5th China Summit Forum on
Industrial Biotechnology Development（Chintao,
May 25-27）.
■ Participation in Global Bio & Medical Forum 2011
（Seoul, June 8‒9）
■ MOU conclusion with Korea BIO（Seoul, June 9）■ Participation in BIO International Convention 2011
（Washington, June 27- July 2）■ Participation in Bio-Europe 2011（Düsseldorf,
October 31-November 2）■ Participation in the 15th Beijing International
Health-care Industry Forum（Beijing November 1-3）
■ Participation in BIO-Asia（Osaka, January 31-February 1）■ Participation in BIO-Europe Spring（Amsterdam,
March 19-21）

Cooperation in OECD activities
The Working Party on Biotechnology（WPB）under theCommittee for Scientific and Technological Policy of
the OECD（Organization for Economic Cooperation
and Development）examines policy issues relating toresearch and development to industrialization throughlife science and biotechnology applied to a wide rangeof areas from medical care and pharmaceutical products
to industry, environment, energy, agriculture and food.

JBA has participated in WPBʼs regular meetings andrelated conferences to support the government, andprovides the status of discussions on a wide range ofpolicy issues to its members. Recently, JBA helped
disseminate its provisional translation of “OECD
Guidelines on Human Biobanks and Genetic Research
Databases” which was adopted as an OECD council
recommendation（March 2010）.

Collection/provision of overseas bio-information
Collection and provision of overseas bioinformation in cooperation with embassies,
regional clusters, etc.
JBA exchanges information with embassies, bioorganizations and regional clusters of Western andAsian countries. JBA provides information about
overseas policies, investment environment, industrial
trends and the research and development situation toits members through its journal “B&I”, etc.

Members of Foreign Embassies・Area・
State Governments, etc. / 31 Agencies
United States, England, Estonia, Australia,
the Netherlands, Canada, Korea, Switzerland,
Sweden, Spain, Chile, Denmark, Germany,
New Zealand, Finland, Malaysia, US・Iowa,
US・Ohio, US・Georgia, US・North Carolina,
US・Pennsylvania, US・Missouri, Australia・
Queensland, Australia・Victoria, Canada・Alberta, Canada・Ontario, Canada・Quebec,
Canada・British Columbia, Scotland, Belgium・
Flanders, Belgium・Wallonia

12

Transmission of overseas policies andindustrial trends through the journal “B&I”

5

Activity Report 2012

actionEstablishing the Infrastructureof Bioindustry
JBA is addressing the improvement of infrastructure for biotechnology and industrial development
in cooperation with member companies, universities and government.

With regard to the enactment process and management of various laws and regulations
on bioindustry in the fields of food and environment, JBA collects and provides related
information, and also holds explanatory meetings to collect and submit opinions fromthe industry.
In addition, JBA establishes various infrastructures for the development of bioindustry
such as support for human resource development in developing countries through JICA,
promotion of national research projects through the management of research associations,fostering of promising young human resources and awarding research prizes.

Corporate members
Venture member
Academia

Information services
Countermeasure
Contact forinquiries Support

Various information on laws andregulations on Intellectual property,
standardization, International treaties,
access to foreign genetic resources（CBD, ABS, GMO, supplement, pharmaceutical）

Human resource
development
Encouraging research
activities

Researchcooperation

Information

Business cooperation

Organization for Economic Cooperation
and Development（OECD）
Japan International Cooperation Agency（JICA）

Research association of Molecular
Dynamics for Antibody Drug Development

Ⅰ Provision of informationon laws and regulations
JBA held an “explanatory meetingon the utilization of the Cartagena Law”

Japan External Trade Organization（JETRO）

a speed-up of the process is expected. Individual
consultations were held after the explanatory meeting.

JBA held an “explanatory meeting on the risk
evaluations of the Cartagena Protocol
and the utilization of the Cartagena Law”
（Jan. 24, Feb. 1-2, 2012）（May 19-20, 2011）

An explanation on the important points on the Industrial
Use of Type 2 substances based of the Cartagena law,the conduction of on-site inspections, the interpretationof GILSP announcement and procedures for obtaining
confirmation abd permission of the Minister was
conducted by The Ministry of Economy, Trade andIndustry. In particular, the process for the confirmationand permission of the Minister was improved, andAn explanation on risk evaluations on living modified
organisms, the mindset for risk management and thetendency of international discussion on risk evaluationof the Cartagena law was conducted by the Ministryof Economy, Trade and Industry and the collective
opinion of the members was consolidated. Individual
consultations and an explanation on the important
points on the industrial use of the Cartagena law werealso held.

13

5

Establishing the Infrastructure of Bioindustry

JBA held a ”Seminar on the Biological
Weapons Convention（BWC）
Before the international congress of Biological Weapons
Convention（WBC）, JBA held related seminars toconsolidate the collective opinions of the members forthe induction of a veriﬁcation system, and to enlighten
and collect opinions of the participants.
① “Present state around the Biological Weapons Convention and its relation with industry”（May 26, 2011）② Seminar on “The security export control from the viewof biosecurity （“ August 4, 2011）

Ⅱ

Biological resources
measures

Support for international
negotiations of CBD and ABS
JBA continuously has participated as a member of thegovernment delegation in international negotiations suchas the Conference of the Parties to the Convention on
Biological Diversity（CBD）and the meetings of working
groups on access to genetic resources and benefit
sharing（ABS）in order to support the government.

③ “Risk management of dual use technology in the
research of life science”

Regulation and policy for advanced
biotechnology① Seminar on “The present state of advanced bioresearch and technology development, and theirpolitical issues”（September 22, 2011）② Seminar on “The technology development in environmental microbe use and its control and issues”（October 25, 2011）2012 Update of Guidelines on Accessto genetic Resources for Users,
based on Nagoya Protocol
Based on the CBD and the principles of the Bonn
Guidelines, JBA published METI-JBA guidelines in March
2005 for Japanʼs overseas genetic resource users. And
based on the Nagoya Protocol of CBD, 2nd edition of theguidelines（in Japanese）wsa issued in March 2012. JBA
has held open seminars in major cities throughout Japanon a continuous basis to enhance public awareness andunderstanding of CBD-ABS.

Help Desk for inquiry about ABS
JBA set up a Help Desk in April 2005 where the issues andproblems relating to access to foreign resources can be
consulted.
Consultations are conducted in a conﬁdential manner andthe number of consultations conducted as of the end of
FY2011 exceeded 380.

Ⅲ

Intellectual property

Based on the opinion of JBA members（interview,questionary, etc.）, JBA annually offers opinions to theIntellectual Property Strategy Headquarters or Japan
Patent oﬃce（JPO）. JBA discussed the issue of intellectual
property（bio-field）with Japan Patent Attorneys
Association（JPAA）.
In addition, under the co-sponsorship with JBA organizes
the “Life Science Intellectual Property Forum” every
year and holds discussions on the issues of intellectual
property related to life science and bioindustry.

14■ Submitted opinions on the formation of the “Intellectual
Property Strategic Program to the Cabinet Office”（January 2011, January 2012）.
■ Survey of companies as to cooperation with universities
and patent application of their results（January to
April 2011）.
■ Publication of the results above; MedU-net General
Meeting（March 2011 and March 2012; Intellectual
Property Association of Japan（June 2011）.
■ Submission of opinions to the Patent Office on “Inventionof Foods speciﬁed by Function” (In cooperation withJAFBIC, November 2011（Observer-participation in
Japan Patent Attorneys Association, March 2012）.

Activity Report 2012

Ⅳ

Human resource
development

JBA Bio-Leaders course
Three-day intensive biotech venture
leadership course for graduate
students and young researchers
in member companies across thecountry, was held from Aug. 1, 2011.

Discussion in groups about the assigned subjects

Top lecture“R&D strategy through the global network and required human resources”
Tatsumi Yamazaki
Excutive Vice President of Chugai PharmaceuticalCo., LtdDr. Tatsumi YamazakiCompletion Certiﬁcate

ⅤAward and grants

JBA promotes scientific research that contributes
to the growth and development of bioindustry byoﬀering award and grants.

JBA Award in 2011
“A
“ASPEXASP
SPEX
EX tectechnology（Fission yeastbased protein expression system）
and its business development ”
Hiromichi Kumagai
Asahi Glass Co.,Ltd. ASPEX Division

The Grant for Research on Chemical
and Biological Materials in 2011“D
“Development
Developmof highly sensitive detection system for
C-reactive protein based on nano-structural change of
enzyme-aptamer complex”
Kazunori Ikebukuro Professor, Tokyo University of Agriculture andTechnology“Development of a platform technology for the preparation of highly eﬃcient biocatalysts using thermostable
enzymes”
Ryuichi Hirota Assistant Professor, Hiroshima University“Protein crystallization in semi-solid agarose gel for thedevelopment of medicines”
Hiroyoshi Matsumura Associate Professor. Osaka University

Dr. Hiromichi Kumagai

Fermentation and Metabolism
Research Grant in 2011
“Acttinomy“Actinomycetes
secondary metabolism for innovationin natural medicines”
Shigeru Kitani Assistant Professor, Osaka University“Rapid construction of unusual peptide libraries byintegrating in vitro translation system and post-translational
enzymes”
Yuki Goto Assistant Professor, The University of Tokyo“Cell sorting on photo-cleavable PEG-lipid surfaces”“Clariﬁcation of tolerance mechanisms to environmental
stress in industry yeast and application to food and environmental industries”

Satoshi Yamaguchi Assistant Professor, The University of Tokyo

Jun Shima Professor, Kyoto University

15

Japan Bioindustry Association
Grande bldg. 8F
2-26-9 Hatchobori Chuo-ku Tokyo 104-0032, Japan
TEL+81-3-5541-2731 FAX+81-3-5541-2737
URL: http://www.jba.or.jp/

Access：A-4 Exit Hatchobori sta. Tokyo metro Hibiya line
Chuo-dori St

Highway

Sotobori-dori St
To Yurakucho

Hatchobori sta.

Takaracho sta.

Hatchobori juncYaesu-dori Av.
Kyobashi sta.

Yaesu exit

Tokyo sta.

To Kanda

A4 exitGrande bldg

Kajibashi-dori St

Shinohashi-dori St
Showa-dori St